Literature DB >> 33489595

A Rare Double Heterozygous Mutation in Low-Density Lipoprotein Receptor and Apolipoprotein B-100 Genes in a Severely Affected Familial Hypercholesterolaemia Patient.

Lilla Juhász1, István Balogh2, László Madar2, Beáta Kovács3, Mariann Harangi1.   

Abstract

Familial hypercholesterolaemia (FH) is characterized by high plasma low-density lipoprotein cholesterol (LDL-C) levels and premature cardiovascular disease risk. Mutations in the genes that encode proteins involved in LDL uptake and catabolism, including LDL-receptor (LDLR) and apolipoprotein-B (APOB), are known to cause FH. We present the case of a severely affected FH proband with two mutations in two different causing genes and characterize her first-degree blood relatives. The proband was a 54-year-old woman with a severe FH phenotype with treated LDL-C of 8.3 mmol/L, total cholesterol (TC) level of 11.6 mmol/L, peripheral artery disease, early myocardial infarction, aortic stenosis, and carotid artery disease. Exons of the LDLR and APOB genes were amplified by polymerase chain reactions (PCR). PCR products were examined by pyrosequencing and proven by bidirectional DNA sequencing. The proband was heterozygous for both the LDLR c.420G>C (p.Glu140Asp) mutation known to be pathogenic and a rare APOB c.10708C>T (p.His3570Tyr) mutation with unproven pathogenicity. Cascade testing has been performed in her 15 first-degree blood relatives. Her daughter carries only the LDLR c.420 G>C mutation with a TC of 8.4 mmol/L. Her two sisters carry only the APOB c.10708C>T with a TC of 5.7 and 6.2 mmol/L. This case provides evidence that the rare APOB c.10708C>T mutation alone is not pathogenic, but has a synergic effect on LDLR mutation. The finding is important for understanding the genotype-phenotype correlation and highlights the need to consider the presence of additional mutations in FH families where relatives have varying phenotypes.
Copyright © 2020, Juhász et al.

Entities:  

Keywords:  autosomal dominant hypercholesterolaemia; double heterozygous; familial hypercholesterolaemia; phenotype

Year:  2020        PMID: 33489595      PMCID: PMC7814514          DOI: 10.7759/cureus.12184

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  19 in total

1.  H3543Y mutation of apoB-100 in patients with phenotype of familial hypercholesterolemia.

Authors:  Zuzana Basistová; Juraj Gasparovic; Daniela Siváková; Katarína Raslová
Journal:  Atherosclerosis       Date:  2006-10-16       Impact factor: 5.162

2.  Spectrum of low density lipoprotein receptor mutations in Czech hypercholesterolemic patients.

Authors:  Viera Kuhrová; Hana Francová; Petra Zapletalová; Tomás Freiberger; Lenka Fajkusová; Eva Hrabincová; Romana Slováĉková; Libor Kozák; Romana Slováková
Journal:  Hum Mutat       Date:  2002-01       Impact factor: 4.878

3.  Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada.

Authors:  S N Pimstone; X M Sun; C du Souich; J J Frohlich; M R Hayden; A K Soutar
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-02       Impact factor: 8.311

4.  Compound heterozygous LDLR variant in severely affected familial hypercholesterolemia patient.

Authors:  Faisal A Al-Allaf; Abdullah Alashwal; Zainularifeen Abduljaleel; Mohiuddin M Taher; Abdellatif Bouazzaoui; Hala Abalkhail; Ahmad F Al-Allaf; Mohammad Athar
Journal:  Acta Biochim Pol       Date:  2016-11-23       Impact factor: 2.149

5.  A double heterozygote for familial hypercholesterolaemia and familial defective apolipoprotein B-100.

Authors:  Alison Taylor; Graham Bayly; Kunjan Patel; Laura Yarram; Maggie Williams; Julian Hamilton-Shield; Steve E Humphries; Gail Norbury
Journal:  Ann Clin Biochem       Date:  2010-08-24       Impact factor: 2.057

6.  Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.

Authors:  Barbara Sjouke; D Meeike Kusters; Iris Kindt; Joost Besseling; Joep C Defesche; Eric J G Sijbrands; Jeanine E Roeters van Lennep; Anton F H Stalenhoef; Albert Wiegman; Jacqueline de Graaf; Sigrid W Fouchier; John J P Kastelein; G Kees Hovingh
Journal:  Eur Heart J       Date:  2014-02-28       Impact factor: 29.983

Review 7.  Genetic heterogeneity of autosomal dominant hypercholesterolemia.

Authors:  M Varret; M Abifadel; J-P Rabès; C Boileau
Journal:  Clin Genet       Date:  2007-11-16       Impact factor: 4.438

Review 8.  Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics.

Authors:  Sang Hak Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2017-01-19

Review 9.  Mechanisms of disease: genetic causes of familial hypercholesterolemia.

Authors:  Anne K Soutar; Rossi P Naoumova
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2007-04

10.  Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.

Authors:  Marina Cuchel; Eric Bruckert; Henry N Ginsberg; Frederick J Raal; Raul D Santos; Robert A Hegele; Jan Albert Kuivenhoven; Børge G Nordestgaard; Olivier S Descamps; Elisabeth Steinhagen-Thiessen; Anne Tybjærg-Hansen; Gerald F Watts; Maurizio Averna; Catherine Boileau; Jan Borén; Alberico L Catapano; Joep C Defesche; G Kees Hovingh; Steve E Humphries; Petri T Kovanen; Luis Masana; Päivi Pajukanta; Klaus G Parhofer; Kausik K Ray; Anton F H Stalenhoef; Erik Stroes; Marja-Riitta Taskinen; Albert Wiegman; Olov Wiklund; M John Chapman
Journal:  Eur Heart J       Date:  2014-07-22       Impact factor: 35.855

View more
  1 in total

1.  Identification of New Genetic Determinants in Pediatric Patients with Familial Hypercholesterolemia Using a Custom NGS Panel.

Authors:  Lena Rutkowska; Kinga Sałacińska; Dominik Salachna; Paweł Matusik; Iwona Pinkier; Łukasz Kępczyński; Małgorzata Piotrowicz; Ewa Starostecka; Andrzej Lewiński; Agnieszka Gach
Journal:  Genes (Basel)       Date:  2022-06-01       Impact factor: 4.141

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.